The FDA determined that Novo Nordisk’s obesity and diabetes drugs are no longer in short supply. Elsewhere, Concentra made a ...
Aardvark Therapeutics has followed up filings and speculation with a $94 million initial public offering, putting itself on ...
Approval could come rather soon. Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once ...
Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in ...
Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...
Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian.
Pfizer has agreed to pay $59,746,277.54, plus interest, to resolve allegations that Biohaven knowingly submitted or caused false claims to be submitted to Medicaid and other federal health care ...
Other recent buys include Biohaven for US$11.6bil and Arena Pharmaceuticals for US$6.7bil. In May, Pfizer embarked on a cost-cutting plan meant to save US$1.5bil by the end of 2027. Still ...
Tong’s office said Pfizer had agreed to pay the sum on behalf of New Haven-based Biohaven to resolve allegations that Biohaven had knowingly submitted or caused to be submitted false claims to ...
Second, the returns on invested capital from Pfizer’s $11 billion Biohaven transaction have also already exceeded the most optimistic internal estimates, with Nurtec sales growing exponentially ...
Florida's Medicaid Fraud Control Unit secured the win through a multistate action. Pharmaceutical giant Pfizer will be paying more than $2.3 million on behalf of its wholly owned subsidiary ...
Unexpected demand for Pfizer Inc.’s Covid vaccine helped the company beat quarterly expectations. Then Robert F. Kennedy Jr., who has been a vocal opponent of the company’s top-selling shot ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results